Pharmacoeconomic evaluation of genotype-guided dabigatran etexilate dosing in patients with atrial fibrillation and chronic kidney disease
- Autores: Mikhaylenko E.V1, Tchubarev V.N1, Abdullaev S.P2, Skripka A.I1, Sychev D.A2
-
Afiliações:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)
- Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
- Edição: Nº 4S (2022): Supplement
- Páginas: 79-83
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277064
- DOI: https://doi.org/10.18565/therapy.2022.4suppl.80-84
- ID: 277064
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Pharmacogenetic testing (PGT) is one of the promising personalized approaches to prescribing drugs in clinical practice. The PGT’s feasibility plays an important role in the oral anticoagulants (DOACs) administration, especially in the event of adverse reactions -hemorrhagic and thrombotic complications. According to the results of our study, personalized pharmacotherapy of dabigatran etexilate 110 and 150 mg reduced the frequency of bleeding (17,79 vs 18,10) and slightly exceeded the cost (cost difference was 216,55 rubles) compared with standard therapy in patients with atrial fibrillation in combination with chronic kidney disease. The PGT application can be used to improve the safety of DOAC pharmacotherapy. In the future, it is possible to decrease the costs of a medical organizations by reducing the cost of genetic tests.
Palavras-chave
Texto integral
Sobre autores
E. Mikhaylenko
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)
V. Tchubarev
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)
Sh. Abdullaev
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
A. Skripka
I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenov University)
D. Sychev
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Bibliografia
- Benjamin E.J., Muntner P., Alonso A. et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association. Circulation. 2019; 139(10): e56-e528. doi: 10.1161/CIR.0000000000000659.
- Регистр лекарственных средств России (РЛС). Антикоагулянты/Прадакса® Доступ: https://www.rlsnet.ru/drugs/pradaksa-37149 (дата обращения - 27.05.2022).
- Тарифное соглашение на оплату медицинской помощи, оказываемой по Территориальной программе обязательного медицинского страхования города Москвы на 2022 год. Доступ: https://www.mgfoms.ru/medicinskie-organizacii/tarifi/2022 (дата обращения - 27.05.2022).
Arquivos suplementares
